Pavlo Kot

Eyepoint Pharmaceuticals announces topline results from second pivotal Phase 3 LUCIA trial

Eyepoint Pharmaceuticals announces topline results from second pivotal Phase 3 LUCIA trial
Eyepoint topline LUCIA trial results

Eyepoint Pharmaceuticals announced topline results from LUCIA, its second pivotal Phase 3 clinical trial for DURAVYU for the treatment of wet age-related macular degeneration (AMD).

The company did not disclose specific details or data from the trial in its tweet. This update marks a significant milestone as DURAVYU progresses through the development pipeline focused on therapies for wet AMD.

Earlier, Eyepoint Pharmaceuticals shared new DURAVYU Phase 3 LUGANO data and real world findings at RetinaSociety2026, according to company disclosures. The LUGANO trial previously provided additional insight into DURAVYU’s development for wet AMD. The latest LUCIA topline results represent a continuation of the company’s efforts in advancing this therapy.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.